Engineered Miniature ParTasR Enables Efficient PAMless Genome Editing

Authors:

Abstract
TIGR-Tas system holds great promise for genome-engineering applications owing to its compact size and PAMless targeting capability. However, its low editing efficiency in mammalian cells severely limits its broader utility. Here, we engineered a highly active variant of ParTasR, termed eTasR, through structure-guided rational design of ParTasR combined with co-expression of the 3′→5′ exonuclease TREX2. eTasR increased editing efficiency in mammalian cells from the original average 4.29% to 48.94% with an average 26.52-fold improvement, substantially outperforming the popular PAM-free version of nuclease-SpRY. Moreover, a single AAV delivery of eTasR in vivo effectively alleviates the disease phenotype of hereditary tyrosinemia type I (HT1) mouse model through targeted Hpd editing. Together, these findings establish eTasR as a compact, PAMless, and highly efficient genome editing tool with broad therapeutic and research applications.
Funding Information
  • National Key R&D Program of China (2022YFC3400200)
  • National Key R&D Program of China (2022YFA1103400)
  • National Natural Science Foundation of China (82522046)
  • the CAMS Innovation Fund for Medical Sciences (2026-I2M-SXZX17-01)
  • the CAMS Innovation Fund for Medical Sciences (2025-I2M-QN-008)
  • the CAMS Innovation Fund for Medical Sciences (2025-I2M-XHXX-173)
  • the CAMS Innovation Fund for Medical Sciences (2025-I2M-XHCL-077)
  • non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2022-RC180-08)